Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation monthly Stock Chart
Celgene Corporation
IndexS&P 500 P/E40.51 EPS (ttm)3.22 Insider Own0.20% Shs Outstand781.92M Perf Week-0.82%
Market Cap101.88B Forward P/E14.62 EPS next Y8.91 Insider Trans-15.15% Shs Float771.80M Perf Month-5.48%
Income2.60B PEG1.85 EPS next Q1.88 Inst Own80.10% Short Float1.18% Perf Quarter11.06%
Sales12.19B P/S8.36 EPS this Y28.10% Inst Trans1.86% Short Ratio2.34 Perf Half Y9.24%
Book/sh10.82 P/B12.04 EPS next Y21.72% ROA9.10% Target Price150.17 Perf Year14.09%
Cash/sh12.97 P/C10.05 EPS next 5Y21.84% ROE36.70% 52W Range96.93 - 139.00 Perf YTD12.56%
Dividend- P/FCF24.33 EPS past 5Y11.80% ROI11.70% 52W High-6.78% Beta1.92
Dividend %- Quick Ratio3.90 Sales past 5Y18.30% Gross Margin96.30% 52W Low33.69% ATR2.49
Employees7132 Current Ratio4.10 Sales Q/Q18.70% Oper. Margin27.60% RSI (14)41.98 Volatility1.77% 1.87%
OptionableYes Debt/Eq1.69 EPS Q/Q75.10% Profit Margin21.30% Rel Volume0.43 Prev Close130.29
ShortableYes LT Debt/Eq1.63 EarningsJul 27 BMO Payout0.00% Avg Volume3.90M Price129.58
Recom1.80 SMA20-2.62% SMA50-1.91% SMA2005.68% Volume555,119 Change-0.54%
Jul-31-17Upgrade Argus Hold → Buy
Jul-28-17Resumed Stifel Buy $155
Jul-11-17Resumed Jefferies Buy
Jun-30-17Downgrade BTIG Research Buy → Neutral
Jun-16-17Upgrade Leerink Partners Mkt Perform → Outperform
Jun-01-17Reiterated Mizuho Buy $130 → $134
May-05-17Downgrade Argus Buy → Hold
Mar-09-17Initiated UBS Buy $140
Nov-09-16Downgrade Standpoint Research Buy → Hold
Nov-08-16Initiated Mizuho Buy $130
Jul-15-16Initiated Stifel Buy $138
Apr-29-16Reiterated Sun Trust Rbsn Humphrey Buy $145 → $147
Feb-25-16Initiated Citigroup Buy $130
Jan-20-16Initiated Credit Suisse Outperform
Jan-14-16Initiated Standpoint Research Buy $130
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $145
Jan-07-16Initiated Sun Trust Rbsn Humphrey Buy
Nov-06-15Reiterated UBS Buy $156 → $145
Oct-01-15Upgrade JP Morgan Neutral → Overweight
Sep-09-15Initiated Jefferies Buy
Aug-23-17 09:07AM  Key Developments for Allergan in 2Q17 Market Realist
07:45AM  Trade of the Day: Celgene Corporation (CELG) Stock Flashing Buy Signals InvestorPlace
Aug-22-17 05:29PM  ETF Topper: Biotechnology Isn't Totally on the Outs
03:20PM  What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline? Motley Fool
08:10AM  3 Growth Stocks for Retirees Motley Fool
Aug-17-17 10:36PM  Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy? Motley Fool
01:36PM  Stock Losses Top 1%; These Stocks Hit Sell Signals Investor's Business Daily
09:03AM  The 3 Best Stocks in Healthcare Motley Fool
08:03AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
Aug-16-17 10:08AM  Biogen: Goldman Has Conviction!
08:02AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
Aug-15-17 08:04AM  Why I Love Celgene Corporation Motley Fool
07:36AM  Pfizers Declining-Revenue Products in 2Q17 Market Realist
Aug-14-17 08:41PM  3 Stocks for Retirees to Grow Their Nest Egg Motley Fool
04:18PM  ETFs with exposure to Celgene Corp. : August 14, 2017 Capital Cube
08:05AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
Aug-12-17 08:03AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
Aug-11-17 09:06PM  Edited Transcript of CELG earnings conference call or presentation 27-Jul-17 1:00pm GMT Thomson Reuters StreetEvents
10:17AM  Celgene Corp. breached its 50 day moving average in a Bearish Manner : CELG-US : August 11, 2017 Capital Cube
09:06AM  Luspatercept: Opportunity for Celgenes Long-Term Growth? Market Realist
08:03AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
07:36AM  Ozanimod Could Drive Celgenes Long-Term Growth Market Realist
Aug-10-17 10:36AM  Celgenes Abraxane Continued Steady Growth in 2Q17 Market Realist
09:07AM  Celgenes Otezla Witnessed High Revenue Growth in 2Q17 Market Realist
08:50AM  Major Biotechs Send Short Sellers Running for Cover 24/7 Wall St.
08:20AM  How 2 biotech partners reimagined cancer pact and made it work again for both American City Business Journals
08:04AM  IHS Markit Score downgrades Celgene Corp to 60 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit
07:37AM  How Celgenes Pomalyst Is Positioned after 2Q17 Market Realist
07:30AM  [$$] Sutro Biopharma Reworks Immuno-Oncology Alliance With Celgene The Wall Street Journal
Aug-09-17 04:05PM  Celgenes Revlimid Witnessed High Growth in 2Q17 Market Realist
02:36PM  How Celgene Performed in 2Q17 Market Realist
01:02PM  Analysts Recommendations for Celgene in August 2017 Market Realist
08:18AM  Is This Why bluebird bio Dipped 10.5% in July? Motley Fool
08:08AM  Biotech Breakouts Suggest It Is Time to Buy Investopedia
08:03AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
08:01AM  Why BeiGene Soared 56.6% In July Motley Fool
Aug-08-17 09:12AM  Agios (AGIO) Q2 Loss Wider than Expected; Sales Miss Zacks
Aug-07-17 03:20PM  bluebird bio Pauses During 2017 Data Blitz Motley Fool
Aug-06-17 03:50PM  Benzinga's Bulls & Bears For The Past Week: Apple, Tesla, Twitter And More Benzinga
Aug-04-17 05:04PM  Celgene vs. Gilead Sciences: Who Reported Better Earnings? Motley Fool
01:21PM  3 Value Stocks for Every Investor Motley Fool
Aug-03-17 06:34PM  Juno Therapeutics' Cash Position and Potential Cash Cow JCAR017 Are Still What's Important Motley Fool
09:25AM  Looking to Buy Some Celgene? Now's a Good Time
08:24AM  Celgene CEO: Time to think about health care in a differe... CNBC Videos
08:15AM  Celgene CEO: Precision medicine targeting metabolic drive... CNBC Videos
06:00AM  Op-Ed: Getting patients access to 'precision' medicines is crucial CNBC
Aug-02-17 04:07PM  This Small Biotech Launched To A 9-Month High Today Here's Why Investor's Business Daily
08:32AM  Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote Zacks
08:00AM  Earnings Preview: What To Expect From Regeneron Pharmaceuticals On Thursday Forbes
Aug-01-17 03:06PM  FDA approves leukemia treatment developed by Celgene, Agios Reuters
11:30AM  FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation Business Wire
11:21AM  FDA approves leukemia treatment developed by Celgene, Agios Reuters
11:09AM  The Zacks Analyst Blog Highlights: Bank of America, UnitedHealth, Intel, UPS and Celgene Zacks
09:35AM  Celgene Corporation -- Moody's assigns Baa2 to Celgene's notes; stable outlook Moody's
08:52AM  Trade of the Day: Celgene Corporation (CELG) InvestorPlace
07:00AM  Featured Company News Dynavax Announces FDA Advisory Committee Vote in Favor of HEPLISAV-B(TM) ACCESSWIRE
06:00AM  3 Stocks With Disney-Like Return Potential Motley Fool
Jul-31-17 06:30PM  Top Analyst Reports for Bank of America, UnitedHealth, Intel & Celgene Zacks
01:40PM  Celgene Corp. :CELG-US: Earnings Analysis: Q2, 2017 By the Numbers : July 31, 2017 Capital Cube
12:35PM  The Celgene Story Is Bigger Than Revlimid Now; Argus Upgrades Benzinga
Jul-28-17 04:30PM  Celgene Corporation Continues to Get It Done Motley Fool
07:30AM  Celgene Corporation to Webcast at Upcoming Investor Conference Business Wire
01:24AM  Celgene beats Street 2Q forecasts Associated Press
Jul-27-17 04:29PM  Biotech Fever Cools As These Players Dip On Longer-Term Views Investor's Business Daily
04:05PM  Benzinga's Option Alert Recap From July 27 Benzinga
12:39PM  Biotechs Sell-Side Roundup: Cowens Take on Gilead Sciences, Inc. (GILD) and Celgene Corporation (CELG) SmarterAnalyst
12:04PM  Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View Zacks
11:37AM  Revlimid drives Celgene profit beat; raises EPS forecast Reuters
10:27AM  AstraZeneca Beats, But Stock Dives On Drug Failure; 4 More Report Investor's Business Daily
08:22AM  Celgene (CELG) Beats on Q2 Earnings & Sales Zacks
07:47AM  Celgene shares surge 1.6% on second-quarter profit, revenue beats MarketWatch
07:41AM  Celgene's profit rises 77.4 pct on Revlimid demand Reuters
07:30AM  Celgene Reports Second Quarter 2017 Operating and Financial Results Business Wire
06:42AM  The Fed Hints at Pausing Interest Rate Hikes, and That's a Good Thing: Market Recon
Jul-26-17 06:06PM  Analysts Recommendations for Bristol-Myers Squibb in 2Q17 Market Realist
12:15PM  Celgene 2Q Preview: Rising Earnings, Revenue Investopedia
12:09PM  A Drug Program That Keeps Patients Safe (And Profits, Too) Bloomberg
10:55AM  What's in Store for Agios Pharma (AGIO) in Q2 Earnings? Zacks
09:37AM  Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN Zacks
09:35AM  Short Sellers Run for Cover From Major Biotech Stocks 24/7 Wall St.
08:07AM  Early movers: KO, BA, F, DHI, HLT, ANTM, NOC, T, APRN, AMGN & more CNBC
01:11AM  Pharmaceutical company Celgene settles suit for $280 million Associated Press
Jul-25-17 10:59PM  Celgene Corp. to pay $280M to settle cancer drug fraud suit Associated Press
06:58PM  [$$] Celgene Settles Lawsuit Over Improper Promotion of Cancer Drugs The Wall Street Journal
05:48PM  Business Highlights Associated Press
05:30PM  Biotech still has more room to run: Technician CNBC Videos
04:57PM  Celgene Corp. to pay $280 million to settle lawsuit alleging it promoted cancer drugs for unapproved uses Associated Press
04:48PM  Celgene to pay $280 mln to settle off-label marketing case Reuters
04:00PM  Celgene Corporation Announces Settlement of Civil Litigation Business Wire
03:28PM  Celgene Settles 'Whistle Blower' Lawsuit for $280 Million
02:54PM  Celgene Settles Whistle-Blower Fraud Suit for $280 Million Bloomberg
11:00AM  3 Stocks You Can Safely Own Until 2030 Motley Fool
06:00AM  Risk-On Attitude Drive Stocks and Biotech Higher Investopedia
Jul-24-17 04:45PM  Biotechs Find Strength In Numbers In Treating Multiple Sclerosis Investor's Business Daily
11:51AM  2 Ways To Trade This Week's Healthcare Earnings Benzinga
10:25AM  Is Celgene (CELG) Poised For a Beat This Earnings Season? Zacks
Jul-23-17 07:27AM  These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet Motley Fool
Jul-22-17 11:43AM  Better Buy: Celgene Corporation vs. Gilead Sciences, Inc. Motley Fool
Jul-21-17 04:14PM  Biotechs On A Hot Streak, And Could Be 'Cooking With Gas' Investor's Business Daily
03:06PM  Nothing Can Keep Celgene Down
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARIO ERNESTDirectorAug 10Sale130.5218,5062,415,40369,424Aug 14 04:53 PM
KAPLAN GILLADirectorAug 02Sale134.527,5001,008,90076,301Aug 03 04:45 PM
Curran TerrieSee remarksAug 01Option Exercise0.001,50006,210Aug 02 04:38 PM
KELLOGG PETER NSee RemarksAug 01Option Exercise0.0060,000070,833Aug 02 04:37 PM
Smith Scott AndrewSee RemarksJul 28Option Exercise0.005,000045,415Aug 01 05:34 PM
PEHL MICHAEL F.See remarksJul 28Option Exercise0.002,50003,488Aug 01 04:56 PM
HUGIN ROBERT Jsee remarksJul 28Option Exercise0.0044,50001,021,159Aug 01 04:52 PM
Alles Mark JSee RemarksJul 28Option Exercise0.004,2000175,120Aug 01 04:48 PM
MARIO ERNESTDirectorJul 01Option Exercise0.00734087,930Jul 05 07:33 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00734024,361Jul 05 07:33 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073400Jul 05 07:31 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00734083,801Jul 05 07:32 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073400Jul 05 07:30 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00734023,880Jul 05 07:31 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00734012,066Jul 05 07:29 PM
LOUGHLIN JAMES JDirectorJun 26Option Exercise29.4318,500544,36332,877Jun 27 04:39 PM
LOUGHLIN JAMES JDirectorJun 26Sale133.5718,5002,471,04523,627Jun 27 04:39 PM
Friedman Michael ADirectorJun 22Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
HUGIN ROBERT Jsee remarksJun 22Option Exercise29.49178,7205,271,0061,033,909Jun 23 04:02 PM
Friedman Michael ADirectorJun 22Sale135.005,000675,0000Jun 23 04:04 PM
HUGIN ROBERT Jsee remarksJun 22Sale134.14175,97023,604,616973,909Jun 23 04:02 PM
Friedman Michael ADirectorJun 21Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Option Exercise33.889,250313,3909,250Jun 23 04:05 PM
Friedman Michael ADirectorJun 21Sale130.005,000650,0000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Sale133.059,2501,230,7130Jun 23 04:05 PM
Friedman Michael ADirectorJun 19Option Exercise59.065,000295,3000Jun 20 04:07 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00333087,196Jun 20 04:09 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00333023,627Jun 20 04:08 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333083,067Jun 20 04:08 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
VESSEY RUPERTSee remarksJun 15Option Exercise104.164,007417,3584,785Jun 16 04:11 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375086,863Jun 16 04:11 PM
KAPLAN GILLADirectorJun 15Option Exercise0.00375082,734Jun 16 04:09 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.00375023,294Jun 16 04:10 PM
Haller Julia ADirectorJun 15Option Exercise0.003750575Jun 16 04:09 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 16 04:08 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.003750375Jun 16 04:06 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 16 04:06 PM
VESSEY RUPERTSee remarksJun 15Sale120.184,785575,0380Jun 16 04:11 PM
KAPLAN GILLADirectorJun 01Option Exercise28.979,250267,92682,359Jun 02 04:11 PM
CASEY MICHAEL DDirectorMay 30Option Exercise28.979,250267,926100,612May 31 04:10 PM
LOUGHLIN JAMES JDirectorMay 01Option Exercise28.969,250267,88032,169May 02 04:20 PM
LOUGHLIN JAMES JDirectorMay 01Sale124.009,2501,147,00022,919May 02 04:20 PM
HUGIN ROBERT Jsee remarksApr 10Option Exercise29.0260,0001,741,200973,909Apr 12 04:24 PM
KAPLAN GILLADirectorMar 30Sale123.8314,0331,737,70673,109Mar 31 05:31 PM
KAPLAN GILLADirectorMar 03Option Exercise25.587,500191,81387,142Mar 07 04:37 PM
VESSEY RUPERTSee remarksMar 01Sale124.424,000497,672778Mar 02 04:04 PM
CASEY MICHAEL DDirectorFeb 27Option Exercise25.587,500191,8507,500Mar 01 04:15 PM
CASEY MICHAEL DDirectorFeb 27Sale121.557,500911,6250Mar 01 04:15 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62306,773Feb 06 04:14 PM
Celgene Switzerland LLC10% OwnerFeb 01Buy16.00625,00010,000,0003,456,463Feb 01 04:18 PM
HUGIN ROBERT Jsee remarksJan 05Option Exercise27.4322,708622,767913,909Jan 09 04:11 PM
Smith Scott AndrewSee RemarksDec 23Option Exercise0.006,400039,875Dec 27 04:17 PM
PEHL MICHAEL F.See remarksDec 02Option Exercise0.001,88001,880Dec 06 04:05 PM
Smith Scott AndrewSee RemarksDec 02Option Exercise0.003,750035,419Dec 06 04:05 PM
FOUSE JACQUALYN Asee remarksDec 02Option Exercise0.005,000084,392Dec 06 04:04 PM
Alles Mark JSee RemarksDec 02Option Exercise0.006,5600166,134Dec 06 04:03 PM
VESSEY RUPERTSee remarksNov 22Sale123.182,500307,9501,150Nov 30 04:15 PM
PEHL MICHAEL F.See remarksNov 10Option Exercise68.3920,4241,396,77022,052Nov 15 04:22 PM
PEHL MICHAEL F.See remarksNov 10Sale121.0422,0522,669,1490Nov 15 04:22 PM
Friedman Michael ADirectorNov 09Option Exercise31.8018,600591,48018,600Nov 10 04:14 PM
HUGIN ROBERT Jsee remarksNov 09Sale120.00100,00012,000,000922,201Nov 14 05:47 PM
Friedman Michael ADirectorNov 09Sale116.1018,6002,159,4600Nov 10 04:14 PM
CELGENE CORP /DE/10% OwnerOct 24Buy14.00800,15011,202,1004,834,980Oct 26 04:15 PM
CASEY MICHAEL DDirectorOct 18Option Exercise100.067,500750,45092,985Oct 19 04:16 PM
Friedman Michael ADirectorOct 03Option Exercise29.8656,1161,675,36456,116Oct 05 04:09 PM
Friedman Michael ADirectorOct 03Sale103.6656,1165,816,9850Oct 05 04:09 PM
BARKER RICHARD WDirectorSep 23Option Exercise36.9220,000738,40031,332Sep 26 04:08 PM
BARKER RICHARD WDirectorSep 23Sale110.8220,0002,216,40011,332Sep 26 04:08 PM
MARIO ERNESTDirectorSep 23Sale109.4215,0001,641,30090,058Sep 26 04:08 PM
KAPLAN GILLADirectorSep 19Option Exercise29.267,500219,45079,642Sep 20 04:42 PM
KAPLAN GILLADirectorSep 15Sale106.449,7101,033,53272,142Sep 16 04:15 PM